Goldman Sachs
PDSB icon

Goldman Sachs’s PDS Biotechnology PDSB Stock Holding History

Goldman Sachs’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.85K Buy
+10,048
New +$10.7K ﹤0.01% 6485
2024
Q3 		– Sell
-317,460
Closed -$930K – 6007
2024
Q2 		$930K Buy
317,460
+226,986
+251% +$726K ﹤0.01% 4456
2024
Q1 		$358K Buy
90,474
+77,988
+625% +$402K ﹤0.01% 4892
2023
Q4 		$62.1K Sell
12,486
-836
-6% -$4.16K ﹤0.01% 5354
2023
Q3 		$67.3K Sell
13,322
-14,376
-52% -$78.7K ﹤0.01% 5243
2023
Q2 		$139K Sell
27,698
-57,473
-67% -$376K ﹤0.01% 5292
2023
Q1 		$524K Buy
+85,171
New +$697K ﹤0.01% 4791
2022
Q2 		– Sell
-29,752
Closed -$184K – 6644
2022
Q1 		$184K Sell
29,752
-2,010
-6% -$12.5K ﹤0.01% 5918
2021
Q4 		$257K Buy
31,762
+20,367
+179% +$219K ﹤0.01% 5750
2021
Q3 		$170K Buy
+11,395
New +$142K ﹤0.01% 5775
2021
Q2 		– Sell
-20,867
Closed -$95K – 6433
2021
Q1 		$95K Buy
20,867
+1,267
+6% +$5.1K ﹤0.01% 5858
2020
Q4 		$42K Buy
+19,600
New +$42.9K ﹤0.01% 5396
2018
Q4 		– Sell
-5,344
Closed -$88K – 5565
2018
Q3 		$88K Sell
5,344
-1,865
-26% -$33.5K ﹤0.01% 5177
2018
Q2 		$149K Buy
7,209
+6,198
+613% +$129K ﹤0.01% 5092
2018
Q1 		$24K Buy
+1,011
New +$272K ﹤0.01% 5638
2017
Q3 		– Sell
-1,824
Closed -$374K – 6797
2017
Q2 		$374K Buy
+1,824
New +$359K ﹤0.01% 5319
2017
Q1 		– Sell
-1,445
Closed -$361K – 6938
2016
Q4 		$361K Buy
+1,445
New +$328K ﹤0.01% 5334
2016
Q3 		– Sell
-2,239
Closed -$453K – 7134
2016
Q2 		$453K Buy
+2,239
New +$396K ﹤0.01% 4933

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Goldman Sachs's PDSB Position: Q2 2026 in Review

Goldman Sachs opened a new position in PDS Biotechnology (PDSB) in Q2 2026: 10,048 shares worth $8.85K. The stake represents ﹤0.01% of the portfolio and ranks #6485 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in PDSB as recently as Q2 2024.

Goldman Sachs first reported a position in PDSB in Q2 2016 and has held it in 18 quarters since. The position peaked at $930K in Q2 2024. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Goldman Sachs held 10,048 shares of PDS Biotechnology worth $8.85K as of Q2 2026.
  • PDS Biotechnology was a new Goldman Sachs position in Q2 2026.
  • PDS Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6485 holding.
  • Goldman Sachs first reported a position in PDS Biotechnology in Q2 2016 and has held it in 18 quarters since.
  • Goldman Sachs's PDS Biotechnology position peaked at $930K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.